CA-VERIMATRIX
18.3.2024 17:46:33 CET | Business Wire | Press release
Regulatory News:
Verimatrix, (Euronext Paris: VMX), the leader in powering the modern connected world with people-centered security, today announced general availability of its new Verimatrix Counterspy anti-piracy solution -- the most advanced anti-piracy technology seen in the past decade.
Counterspy leverages technology first developed by the company's cybersecurity team back in 2021 to offer an innovative new way to counter the rise in video piracy in an era where streaming apps are prevalent. Counterspy is a standalone product within Verimatrix's anti-piracy team, engineered to prevent video content theft, shield apps from attack, and provide ongoing piracy threat prediction, detection and response services.
Counterspy goes beyond traditional methods to ensure top-tier security for media app subscribers, safeguarding content across various devices. It fills the gap in authentication created by the shift from operator-controlled set top box hardware to retail or app-based OTT clients, allowing operators to distribute content confidently while preventing piracy. With Counterspy, each app instance is authenticated and tied to a specific subscriber, ensuring transparency and control over access. By safeguarding the authentication token from theft or manipulation, Counterspy prevents abuse and ensures legitimate access to content, going above and beyond traditional DRM vendors.
What makes Counterspy stand out:
- Unique Protection and Threat Detection from the Video Service Provider to the Consumer Device: Verimatrix Counterspy effortlessly brings security into the unmanaged consumer device via the video app, something that has been lacking since the explosion of OTT streaming services that use consumers’ own devices. Verimatrix combined the best of its anti-piracy technologies with its cybersecurity innovations to create a bold new approach to tackling the piracy problem – a breakthrough leap forward.
- AI/ML-Driven Real-Time Protection: Leveraging the latest in artificial intelligence and machine learning, Counterspy can quickly identify piracy signals and cybersecurity threats, allowing for the real-time deployment of countermeasures.
- Multi-Layered Security Approach: Counterspy builds on proven technologies such as DRM and watermarking, with a new generation of sophisticated app protection and piracy monitoring tools to detect suspicious activity. This allows video service providers to pinpoint suspicious behavior at its source – as it’s happening – to thwart bad actors without impacting the experience of legitimate service subscribers. By shielding the app, Counterspy also protects personal information and payment card details belonging to video service subscribers. This multi-layered approach to video content + app security, along with the ability to deploy real-time anti-piracy countermeasures, allows streaming operators to continuously evolve their response to emerging threats – staying one step ahead of the pirates.
“With our release of Counterspy, Verimatrix is at the forefront of the innovation needed to fight today’s sophisticated pirates within a vastly connected content viewing ecosystem,” said Andrew Bear, head of anti-piracy business at Verimatrix. “Yesterday’s security approaches are no longer enough to protect both revenue and content. Counterspy enables streaming operators to immediately fight back against pirates that seek to use the latest and often unnoticed business-draining techniques. We see Counterspy as a giant leap forward for security in the M&E industry because it can be directly linked to millions of dollars in prevented piracy-related losses as well as notable operating cost savings.”
For operators, Counterspy targets piracy and revenue leakage, enhances content security and app protections, and helps prevent the compromise of user data. A Verimatrix telco customer who deployed an early release version of Counterspy realized an OPEX savings of $300,000, and they prevented direct piracy losses of $21 million in one year. Counterspy's design for speedy and straightforward integration into streaming video clients allows operators to detect and efficiently counteract piracy directly at its source – serving as an "autonomous security solution" that stands in stark contrast to traditional methods.
Counterspy is part of the Verimatrix Streamkeeper suite of security solutions and can be flexibly deployed alongside other Verimatrix technologies, including Multi-DRM and Watermarking. Operators can schedule a demo by clicking here.
A live webinar is scheduled to take place on March 19 at 5 p.m. CET / 9 a.m. PST with security experts from Verimatrix and sports leader beIN discussing piracy in today’s video ecosystem and showing why a combination of classic video protection and cybersecurity is key for success. Presenters include Lee Kent from beIN, Klaus Schenk, SVP Security and Threat Research at Verimatrix, and Maria Malinkowitsch, VP Video Protection Business at Verimatrix. Register here.
A companion white paper has also been made available for download, "Securing the Streaming Seas: Verimatrix Counterspy's Superior Defense Against Piracy In a World Dominated by Video Apps."
About Verimatrix
Verimatrix (Euronext Paris: VMX) helps power the modern connected world with security made for people. We protect digital content, applications, and devices with intuitive, people-centered and frictionless security. Leading brands turn to Verimatrix to secure everything from premium movies and live streaming sports, to sensitive financial and healthcare data, to mission-critical mobile applications. We enable the trusted connections our customers depend on to deliver compelling content and experiences to millions of consumers around the world. Verimatrix helps partners get to market faster, scale easily, protect valuable revenue streams, and win new business. Visit www.verimatrix.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240318045012/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
